Bristol-Myers Squibb Company (BMY) FinancialsBMYBristol-Myers Squibb Company

Bristol-Myers Squibb Company (BMY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Eliquis, accounting for 34.5% of total sales, equivalent to $4.48B. Other significant revenue streams include Opdivo and Orencia. Understanding this composition is critical for investors evaluating how BMY navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Bristol-Myers Squibb Company maintains a gross margin of 68.03%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 37.53%, while the net margin is 25.56%. These profitability ratios, combined with a Return on Equity (ROE) of 46.70%, provide a clear picture of how effectively BMY converts its operational activities into shareholder value.

In the context of the broader market, BMY competes directly with industry leaders such as VRTX and SNY. With a market capitalization of $121.09B, it holds a significant position in the sector. When comparing efficiency, BMY's gross margin of 68.03% stands against VRTX's 85.33% and SNY's 69.24%. Such benchmarking helps identify whether Bristol-Myers Squibb Company is trading at a premium or discount relative to its financial performance.

Bristol-Myers Squibb reported a net income of approximately $7.1 billion for FY 2025, reflecting a significant recovery from a net loss of $8.9 billion in 2024. The gross margin has also improved to 68.03% in Q2 2026, showcasing strong operational efficiency.